Jun 15, 2010
PTPL1/PTPN13 regulates breast cancer cell aggressiveness through direct inactivation of Src kinase
Glondu-Lassis M, Dromard M, Lacroix-Triki M, Nirdé P, Puech C, Knani D, Chalbos D, Freiss G , Cancer Research , Volume 70, Issue 12, pp. 5116-26, May 25, 2010
The protein tyrosine phosphatase PTPL1/PTPN13, the activity of which is decreased through allelic loss, promoter methylation, or somatic mutations in some tumors, has been proposed as a tumor suppressor gene. Moreover, our recent clinical study identified PTPL1 expression level as an independent prognostic indicator of a favorable outcome for patients...
Jun 8, 2010
High-content phenotypic profiling of drug response signatures across distinct cancer cells
Caie PD, Walls RE, Ingleston-Orme A, Daya S, Houslay T, Eagle R, Roberts ME, Carragher NO , Molecular Cancer Therapeutics , doi: 10.1158/1535-7163.MCT-09-1148
The application of high-content imaging in conjunction with multivariate clustering techniques has recently shown value in the confirmation of cellular activity and further characterization of drug mode of action following pharmacologic perturbation. However, such practical examples of phenotypic profiling of drug response published to date have largely been restricted to...
Apr 13, 2010
A Hierarchy of Self-Renewing Tumor-Initiating Cell Types in Glioblastoma
R. Chen, M. C. Nishimura, S. M. Bumbaca, S. Kharbanda, W. F. Forrest, I. M. Kasman, J. M. Greve, R. H. Soriano, L. L. Gilmour, C. Sanchez Rivers, Z. Modrusan, S. Nacu, S. Guerrero, K. A. Edgar, J. J. Wallin, K. Lamszus, M. Westphal, S. Heim, C. D. James, S. R. Van den Berg, J. F. Costello , Cancer Cell , DOI: 10.1016/j.ccr.2009.12.049
The neural stem cell marker CD133 is reported to identify cells within glioblastoma (GBM) that can initiate neurosphere growth and tumor formation; however, instances of CD133− cells exhibiting similar properties have also been reported. Here, we show that some PTEN-deficient GBM tumors produce a series of CD133+ and CD133− self-renewing...
Mar 26, 2010
T cell-dependence of Lassa fever pathogenesis
Flatz L, Rieger T, Merkler D, Bergthaler A, Regen T, Schedensack M, Bestmann L, Verschoor A, Kreutzfeldt M, Brück W, Hanisch UK, Günther S, Pinschewer DD , PLoS Pathog. , e1000836, Mar 26,2010
Lassa virus (LASV), the causative agent of Lassa fever (LF), is endemic in West Africa, accounting for substantial morbidity and mortality. In spite of ongoing research efforts, LF pathogenesis and mechanisms of LASV immune control remain poorly understood. While normal laboratory mice are resistant to LASV, we report that mice...
Mar 1, 2010
Safety and Efficacy of an Inhaled Epidermal Growth Factor Receptor Inhibitor (BIBW 2948 BS) in Chronic Obstructive Pulmonary Disease
P. G. Woodruff, M. Wolff, J. M. Hohlfeld, N. Krug, M. T. Dransfield, E. R. Sutherland, G. J. Criner, V. Kim, A. Prasse, M. C. Nivens, K. Tetzlaff, R. Heilker, J. V. Fahy , American journal of respiratory and critical care medicine , DOI: 10.1164/rccm.200909-1415OC
Rationale: Epidermal growth factor receptor (EGFR) activation is implicated in mucin hypersecretion in chronic obstructive pulmonary disease (COPD).Objectives: To investigate the safety and efficacy of an inhaled EGFR antagonist (BIBW 2948) in COPD.Methods: Multicenter, double-blind, placebo-controlled trial of 4 weeks of treatment with two doses of BIBW 2948 (15 and...